Trekrezan in 80 outpatients with fatigue after COVID-19
Comparison in people · 2021
- What was studied
- 80 adults within one month of outpatient COVID-19. Trekrezan: 40. Comparison with no Trekrezan: 40.
- Main finding
- After eight days, 32 of 40 Trekrezan recipients and 8 of 40 controls had no fatigue on the study scale. The 2021 and 2022 reports describe the same 80 patients.
No asthenia · 32/40 (80%) vs 8/40 (20%) · Day 8
Reported findings and study design
Short-term parallel comparison using the Asthenic State Scale, Hospital Anxiety and Depression Scale, and a subjective sleep questionnaire.
Population or model 80 adults within one month of outpatient COVID-19. Trekrezan: 40. Comparison with no Trekrezan: 40.
Dose, route and schedule
Oral Trekrezan 600 mg on day 1, then 200 mg/day for seven days (2,000 mg total).
Protocol source ↗ · Original 2021 article record and full 2022 companion article, including Table 2.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| No asthenia | 32/40 (80%) vs 8/40 (20%) | Day 8 |
| Moderate or severe asthenia | 0/40 vs 18/40 (45%) | Day 8 |
Asthenia categories at baseline and day 8
| Category | Trekrezan baseline | Trekrezan day 8 | Control baseline | Control day 8 |
|---|---|---|---|---|
| None | 0 | 32 | 0 | 8 |
| Mild | 4 | 8 | 4 | 14 |
| Moderate | 28 | 0 | 29 | 16 |
| Severe | 8 | 0 | 7 | 2 |
Table 2 of the full companion publication. Each column contains 40 participants. Companion DOI: 10.24412/2311-1623-2022-33.1-24-30.
Source for these results ↗ · Reviewed 2026-11-15
Study limitations and source details
Study limitations
- The authors report randomization. The comparison group received no placebo, and fatigue was assessed by questionnaire. Follow-up was eight days.
Related publications may describe some of the same participants or experiments.
Source details
Original 2021 article record and full 2022 companion article, including Table 2.
Sources checked
Citation
I. B. Zueva, Y. V. Kim, M. Y. Suslova. Trekrezan in 80 outpatients with fatigue after COVID-19 Therapy. 2021;7(6):156–162. Companion report: International Heart and Vascular Disease Journal. 2022;10(33.1):24–30.
Study source ↗ · DOI 10.18565/therapy.2021.6.156-162 · Bibliography entry · Link to this summary